Alnylam Pharmaceuticals
ALNY
$174.00
-25.13%
Alnylam Pharmaceuticals is the pioneer and commercial leader of RNA interference (RNAi) therapeutics, a platform that silences disease-causing genes at their source; its commercial portfolio includes Amvuttra and Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, and Oxlumo for primary hyperoxaluria, alongside partner-led Leqvio (Novartis) and Qfitlia (Sanofi). The company's identity is that of a platform-defining biotech rather than a single-asset story, with an expansive clinical pipeline spanning cardio-metabolic disease, neuroscience, and hematology that gives it optionality beyond its current rare-disease franchises. The investor debate has shifted from 'can RNAi work?' to 'how durable and how large is the commercial runway?', with the stock under heavy pressure in 2026 despite a swing into solid GAAP profitability and 67% revenue growth, as guidance disappointment and competitor news in the amyloidosis space have driven a sharp de-rating. Recent coverage frames the central tension bluntly: Alnylam is now solidly profitable, yet the market is treating it like a broken biotech, leaving bulls arguing the selloff is overdone and bears focused on competitive encroachment and pipeline execution risk.…
ALNY
Alnylam Pharmaceuticals
$174.00
Related headlines
Investment Opinion: Should I buy ALNY Today?
Rating: Buy (speculative growth). The core thesis is that Alnylam has transformed into a profitable, cash-generating RNAi platform trading at a forward PE of 18.1x—a valuation that embeds excessive pessimism given 67% revenue growth and a $368.70 average analyst target (65% upside). The consensus rating of 1.67 ('buy') across 27 analysts reinforces that the Street sees the selloff as overdone.
Supporting evidence is strong: Q2 2026 revenue of $1.29B grew 66.9% YoY; gross margin is 76.9% and operating margin 17.9%; trailing free cash flow is $543M; and ROE is 39.8%. The forward PE of 18.1x compares favorably to the trailing PE of 166x, showing that earnings are expected to inflect sharply. Even the analyst low target of $250 is above the current price, and the high target of $536 implies 139% upside. The main caveats are the 14.0x price-to-sales and 81.9x EV/EBITDA, which are not cheap on absolute terms.
The biggest risks that could invalidate the thesis are: (1) competitive erosion in hATTR amyloidosis causing revenue growth to decelerate below 20%; (2) a failure to deliver the $16.56 forward EPS, which would make the 18x forward PE illusory; and (3) high leverage (D/E 1.62x) limiting financial flexibility. The rating would upgrade to a stronger Buy if the stock stabilizes above $250 and revenue growth holds above 50%, and would downgrade to Hold if Q3 revenue growth falls below 30% or if the stock breaks below the $197.81 52-week low. On balance, the stock appears undervalued relative to its growth trajectory and analyst targets, though not cheap on trailing metrics.
Sign up to view all
ALNY 12-Month Price Forecast
The forward-looking view is cautiously bullish because the operating fundamentals are inflecting positively while the stock price has already priced in substantial pessimism. The 51.7% one-year decline and 44% YTD drop have compressed the forward PE to 18.1x, which is attractive if the $16.56 EPS estimate is achievable. The key risk is competitive dynamics in hATTR amyloidosis, which triggered the July 30 28% single-day drop and remains unresolved. I would upgrade to high confidence if Q3 revenue growth exceeds 50% and the stock reclaims $250; I would downgrade to neutral if revenue growth falls below 30% or if the stock breaks below $197.81.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alnylam Pharmaceuticals's 12-month outlook, with a consensus price target around $367.78 and implied upside of +111.4% versus the current price.
Average Target
$367.78
0 analysts
Implied Upside
+111.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$250 - $536
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: ALNY Investment Factors
The bull case rests on exceptional fundamental momentum: 67% revenue growth, a swing to GAAP profitability, $543M in trailing free cash flow, and a 65% upside to the average analyst target. The bear case centers on the market's violent de-rating—a 28% one-day drop in July and a 51.7% one-year decline—driven by guidance disappointment and competitive threats in amyloidosis, compounded by still-elevated trailing multiples and high leverage. On balance, the evidence currently favors the bulls on operating performance, but the bears have the momentum and the market's vote. The single most important tension is whether the July guidance reset reflects a temporary air pocket or the beginning of structural deceleration in the core hATTR franchise; how that resolves will determine whether the forward PE of 18x is a bargain or a value trap.
Bullish
- Revenue growth accelerating at 67% YoY: Q2 2026 revenue reached $1.29B, up 66.9% from $774M in Q2 2025, driven by Amvuttra and the broader RNAi portfolio. This is not a one-quarter anomaly: Q1 2026 revenue of $1.17B grew roughly 96% from $594M in Q1 2025, and Q4 2025 revenue of $1.10B grew 85% from $593M. The trajectory supports the bull case that the commercial runway is far from exhausted.
- Swing to GAAP profitability with expanding margins: Alnylam posted Q2 2026 net income of $164M (EPS $1.23) versus a $66M loss in Q2 2025, with operating margin at 17.9% and gross margin at 76.9%. The trailing twelve-month free cash flow is $543M, and ROE stands at 39.8%, demonstrating that the platform can generate real cash rather than just revenue.
- Analyst consensus target implies 65% upside: The average analyst target price is $368.70 against the current $224.03, with a 'buy' consensus (mean rating 1.67 across 27 analysts). Even the low target of $250 is 11.6% above the current price, suggesting the Street sees the selloff as overdone relative to fundamentals.
- Forward PE of 18x on $16.56 EPS estimate: The forward PE of 18.1x based on estimated EPS of $16.56 is remarkably low for a company growing revenue at 67%. This implies the market is pricing in a severe deceleration or competitive erosion that the current revenue run-rate ($4.7B annualized) does not yet reflect.
Bearish
- Stock down 51.7% in one year, 44% YTD: ALNY has lost more than half its value over the past 12 months and is down 44% year-to-date, massively underperforming the S&P 500 (up 13.1% and 11.5%, respectively). The relative strength of -64.8% over one year signals a deep loss of confidence that may not reverse quickly.
- Valuation still rich on most metrics: Despite the selloff, the trailing PE is 166x, price-to-sales is 14.0x, price-to-book is 66.0x, and EV/EBITDA is 81.9x. Even the forward PE of 18.1x relies on EPS jumping from $0.006 trailing to $16.56, a heroic assumption that leaves little room for execution missteps.
- Guidance disappointment and competitive news: The sharp drop from $286.62 on July 29 to $205.48 on July 30 (a 28% single-day decline) coincided with guidance disappointment and competitor news in amyloidosis. This suggests the market is re-rating the growth durability of the core franchise, not just reacting to a temporary miss.
- High leverage and interest burden: Debt-to-equity is 1.62x, and Q2 2026 interest expense was $82M, consuming a meaningful portion of operating income ($231M). With a current ratio of 2.76 the liquidity is adequate, but the debt load amplifies downside if revenue growth stalls.
ALNY Technical Analysis
Beta
0.27
0.27x market volatility
Max Drawdown
-64.6%
Largest decline past year
52-Week Range
$172-$480
Price range past year
Annual Return
-63.9%
Cumulative gain past year
| Period | ALNY Return | S&P 500 |
|---|---|---|
| 1m | -31.5% | +0.7% |
| 3m | -15.3% | +3.0% |
| 6m | -41.2% | +6.8% |
| 1y | -63.9% | +11.9% |
| ytd | -56.5% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALNY Fundamental Analysis
Quarterly Revenue
$1.3B
2026-06
Revenue YoY Growth
+66.9%
YoY Comparison
Gross Margin
76.9%
Latest Quarter
Free Cash Flow
$542543000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALNY Overvalued?
PE
166.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 53x~71x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are meaningful despite the profitability swing. Debt-to-equity of 1.62x and Q2 2026 interest expense of $82M against operating income of $231M mean roughly 35% of operating profit is consumed by interest, leaving a thinner cushion than the income statement headline suggests. Revenue is concentrated in the hATTR amyloidosis franchise (Amvuttra and Onpattro), so any pricing pressure or share loss there would hit the majority of the revenue base. Additionally, the forward EPS estimate of $16.56 versus trailing EPS of $0.006 implies an extraordinary earnings ramp that depends on continued 60%+ growth and margin expansion; a deceleration to 20-30% growth would leave the forward multiple looking far less attractive.
Market and competitive risks are the proximate cause of the de-rating. The stock's beta of 0.269 is low, yet it has fallen 51.7% in a year while the S&P 500 rose 13.1%, indicating company-specific rather than market-driven selling. The July 30 single-day drop of 28% on guidance and competitor news shows how sensitive the shares are to amyloidosis competitive dynamics. Valuation compression risk remains: price-to-sales of 14.0x and EV/EBITDA of 81.9x are premium multiples that assume flawless execution, and any further negative pipeline or competitive headlines could trigger another leg down. The high short ratio of 5.17 amplifies this vulnerability.
The worst-case scenario is a chain in which a competitor erodes Amvuttra's hATTR share, causing revenue growth to decelerate below 20%, which would compress the forward PE and force analysts to cut targets. In that scenario, the stock could retest its 52-week low of $197.81, representing a 11.7% decline from the current $224.03, and a more severe re-rating toward the analyst low target of $250 is actually above the current price, highlighting how far sentiment has fallen. A deeper drawdown toward the historical max drawdown of -58.17% from the 52-week high of $485.36 would imply a price near $203, roughly 9% below current levels. Realistically, investors could lose 12-20% from here in an adverse scenario, with the 52-week low as the first major support.
FAQ
The most severe risk is competitive encroachment in hATTR amyloidosis, which triggered a 28% single-day decline on July 30 and remains the central threat to the revenue base. Second is financial leverage: debt-to-equity of 1.62x and $82M quarterly interest expense consume about 35% of operating income, reducing flexibility. Third is valuation compression risk, as the 14.0x price-to-sales and 81.9x EV/EBITDA leave little room for execution missteps. Fourth is pipeline execution risk across cardio-metabolic and neuroscience programs, where failures would remove optionality. These risks are ranked from most to least immediate, with the competitive threat being the most likely to cause further downside.
The 12-month forecast has three scenarios: a bull case (30% probability) targeting $368-$536 if revenue growth stays above 50% and sentiment recovers; a base case (50% probability) targeting $250-$300 as growth moderates to 30-40% and the forward PE proves fair; and a bear case (20% probability) targeting $197-$250 if competitive losses accelerate and estimates are cut. The base case is most likely, assuming revenue growth remains above 20% and the $16.56 EPS estimate is largely achieved. The key assumption is that the July guidance reset was a temporary air pocket rather than structural deceleration.
On trailing metrics, ALNY looks expensive: PE of 166x, price-to-sales of 14.0x, and EV/EBITDA of 81.9x. However, these multiples reflect a company that just turned profitable, and the forward PE of 18.1x on estimated EPS of $16.56 tells a very different story. The market is pricing in a sharp earnings inflection, and if that materializes, the stock is undervalued relative to its 67% revenue growth. Compared to the analyst average target of $368.70, the current price of $224.03 is a 39% discount. The valuation implies the market expects growth to decelerate materially, creating an opportunity if that pessimism proves excessive.
From a risk/reward perspective, ALNY offers a compelling asymmetry: the average analyst target of $368.70 implies 65% upside, while the 52-week low of $197.81 implies only 11.7% downside from the current $224.03. The company is now profitable with $543M in trailing free cash flow and 67% revenue growth, yet trades at just 18.1x forward earnings. The biggest downside risk is competitive erosion in hATTR amyloidosis, which could force another guidance cut. For investors with a medium-term horizon and tolerance for volatility, the stock is a good buy at current levels, but position sizing should reflect the high short interest (5.17) and the 28% single-day drop risk demonstrated in July.
ALNY is better suited for long-term holding (minimum 12-18 months) because the thesis depends on the market re-rating a profitable growth story, which takes time. The stock's beta of 0.269 suggests low market correlation, but its 51.7% one-year decline and 28% single-day drop show high idiosyncratic volatility, making it unsuitable for short-term trading unless one has a high risk tolerance. No dividend is paid (payout ratio 0), so returns depend entirely on capital appreciation. Earnings visibility is improving with four consecutive quarters of GAAP profitability, but pipeline binary events add unpredictability. A 12-18 month holding period allows time for the forward EPS estimate to be validated and for sentiment to normalize.